SCHEMBL2482898

SCHEMBL2482898

COC(=O)c1ccc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)c(I)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.48
AKR1C3 P42330 3/20 0.44
AKR1C2 P52895 3/20 0.44
RXRA P19793 2/20 0.44
RXRB P28702 2/20 0.44
RXRG P48443 1/20 0.44
PDK2 Q15119 3/20 0.44
GPBAR1 Q8TDU6 1/20 0.43
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TLR2 O60603 1/20 0.41
TLR1 Q15399 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12255368 0.92 NOTUM (0.44) NOTUMAKR1C3AKR1C2RXRARXRB
SCHEMBL2484166 0.83 KDM4E (0.51) NOTUMAKR1C3AKR1C2RXRARXRB
SCHEMBL2387047 0.83 NOTUM (0.61) NOTUMAKR1C3AKR1C2RXRARXRB
SCHEMBL2389831 0.82 RXRA (0.61) AKR1C3AKR1C2RXRARXRBRXRG
SCHEMBL28340583 0.81 EGFR (0.56) HCRTR1HCRTR2KDM4EALDH1A1CA12
SCHEMBL204112 0.80 CA1 (0.55) NOTUMPDK2HCRTR1HCRTR2LMNA
SCHEMBL2389365 0.79 RXRA (0.65) NOTUMRXRARXRBRXRGLMNA
SCHEMBL12255733 0.77 RXRA (0.50) AKR1C3AKR1C2RXRARXRBRXRG
SCHEMBL12255366 0.76 NOTUM (0.56) NOTUMAKR1C3AKR1C2RXRARXRB
SCHEMBL12255362 0.76 KDM4E (0.47) NOTUMAKR1C3AKR1C2PDK2GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2375904-B1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME (US) 2014-05-28 EP disclosed
EP-2375904-B1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME (US) 2014-05-28 EP disclosed
US-8367679-B2 Biaryl carboxamides MERCK SHARP & DOHME CORP. (US) 2013-02-05 US disclosed
US-8367679-B2 Biaryl carboxamides MERCK SHARP & DOHME CORP. (US) 2013-02-05 US disclosed
EP-2375904-A1 BIARYL CARBOXAMIDES Merck Sharp & Dohme Corp. (US) 2011-10-19 EP disclosed
US-20110230498-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. 2011-09-22 US disclosed
WO-2010077624-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. (US) 2010-07-08 WO disclosed
WO-2010077624-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230498-A1 BIARYL CARBOXAMIDES PAFAH1B3, PAFAH1B2, FAAH2 NOTUM 486/4885AKR1C3 292/4885AKR1C2 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.